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Over the last decade assessment of angiogenesis has emerged as a potentially useful biological prognostic and predictive factor
in human solid tumours. With the development of highly speciﬁc endothelial markers that can be assessed in histological
archival specimens, several quantitative studies have been performed in various solid tumours. The majority of published
studies have shown a positive correlation between intra-tumoural microvessel density, a measure of tumour angiogenesis, and
prognosis in solid tumours. A minority of studies have not demonstrated an association and this may be attributed to
signiﬁcant differences in the methodologies employed for sample selection, immunostaining techniques, vessel counting and
statistical analysis, although a number of biological differences may account for the discrepancy. In this review we evaluate the
quantiﬁcation of angiogenesis by immunohistochemistry, the relationship between tumour vascularity and metastasis, and the
clinicopathological studies correlating intra-tumoral microvessel density with prognosis and response to anti-cancer therapy. In
view of the extensive nature of this retrospective body of data, comparative studies are needed to identify the optimum
technique and endothelial antigens (activated or pan-endothelial antigens) but subsequently prospective studies that allocate
treatment on the basis of microvessel density are required.
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Angiogenesis is the process in which new blood vessels arise from
existing ones. This is present physiologically in the adult during
wound healing, the development of the ovarian follicle and corpus
luteum and in the proliferating endometrium. Pathological angio-
genesis is also a component of much diverse pathology ranging
from diabetes and atherosclerosis to cancer, a disease that cannot
progress without the formation of new blood vessels (Folkman,
1972).
The measurement of angiogenesis is complicated by the fact that
it is a dynamic process yet most studies to date have focused on
the product of angiogenesis, the microvessel density, which was
analysed at a particular point in time. Accepting this caveat there
are extensive data in which the microvessel density correlates with
metastasis and survival. Here, we discuss the relationship between
angiogenesis and the intra-tumoural microvessel density (IMD),
review the different techniques that have been used to measure
IMD and then discuss the reasons why this relationship does not
always hold.
IMD AS A MEASURE OF TUMOUR ANGIOGENESIS
As angiogenesis is a dynamic process, comparisons with snapshot
views of the tumour, as are seen in biopsy analyses, are not
straightforward. On the other hand the only approaches that are
available in the clinic for the serial measurement of tumour angio-
genesis involve molecular imaging strategies, such as contrast-
enhanced magnetic resonance imaging (MRI) and positron emis-
sion tomography (PET), that do not resolve data at the
microscopic level. Thus it is important to assess the relationship
between IMD and angiogenesis.
Several studies have reported correlations between IMD and
angiogenic growth factor expression, tumour growth and the
occurrence of distant metastasis suggesting that IMD, as well as
quantifying vascular density, reﬂects important information on
the degree and function of tumour vasculature.
IMD and angiogenic cytokine expression
Several clinicopathological studies have shown a direct association
between angiogenic cytokine expression and IMD. Vascular
endothelial growth factor (VEGF) expression has been shown to
correlate with microvessel density in a number of solid tumours
including prostate (Weidner et al, 1993), colon (Takahashi et al,
1995), lung (Mattern et al, 1996) and breast cancer (Linderholm
et al, 1999). Toi et al (1995a) compared IMD with VEGF and
PdEGF (platelet-derived endothelial cell growth factor) expression
in 152 invasive breast cancer specimens. VEGF and PdEGF expres-
sion were signiﬁcantly correlated with the increase in IMD, and in
another study intra-tumoural VEGF concentrations in 135 breast
cancer tissue homogenates were signiﬁcantly higher in richly vascu-
larised tumours as opposed to the ones that were poorly
vascularised. (Toi et al, 1996). VEGF concentrations measured by
ELISA in the tumour tissue from 19 brain tumour patients were
signiﬁcantly correlated with vascular density (Takano et al, 1996).
Almost all tumour cells in the peripheral areas of brain tumours
that contained a high amount of VEGF protein were associated
with increased IMD on immunohistochemical staining.
Signiﬁcant correlation between VEGF expression and IMD has
also been reported for gastric (Maeda et al, 1996), endometrial
(Giatromanolaki et al, 2001) and cervical cancer (Guidi et al,
1995).
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Received 23 January 2002; accepted 21 March 2002
*Correspondence: Dr G Jayson; E-mail: GordonJayson@aol.com
British Journal of Cancer (2002) 86, 1566–1577
ã 2002 Cancer Research UK All rights reserved 0007–0920/02 $25.00
www.bjcancer.comThe clinical importance of VEGF is emphasised by the fact
that VEGF inhibition has been shown to signiﬁcantly inhibit
angiogenesis and tumour growth in in vivo models (Kim et al,
1993; Saleh et al, 1996). Consequently anti-VEGF agents are
being developed as therapeutic strategies to inhibit tumour
angiogenesis and progression. Clearly these cytokines act through
speciﬁc signalling receptors and recent data have shown a rela-
tionship between cytokine concentration, signalling receptor and
IMD. In a series of 121 endometrial carcinomas, VEGF expres-
sion was associated with increased angiogenesis and poor
prognosis, but more importantly its expression was linked with
an increased density of vessels expressing the KDR (kinase
domain region) receptor at the invading tumour front. VEGF
expression in the absence of VEGF/KDR-activated vasculature
was a less important predictor of poorer survival, suggesting that
the prognostic importance of VEGF is signiﬁcantly improved
when the combined VEGF/KDR status is assessed (Giatromanola-
ki et al, 2001).
A positive correlation between IMD and other angiogenic cyto-
kines like basic ﬁbroblast growth factor (bFGF) has also been
reported (Li et al, 1994; Riedel et al, 2000; Sugamoto et al,
2001). However, several studies failed to ﬁnd any correlation
between bFGF and IMD and have questioned its relevance as an
independent prognostic factor (Burian et al, 1999; Schmidt et al,
1999; Smith et al, 1999). It has been hypothesised that bFGF has
a role only when it synergises with other growth factors like VEGF.
Thymidine phosphorylase (TP or PDECGF), another important
angiogenic factor, is an intracellular enzyme involved in pyrimidine
metabolism, neural function and neovascularisation (Brown et al,
1998). One of its metabolites 2-deoxy-D-ribose is a potent media-
tor of angiogenesis (Folkman, 1996). The prognostic value of TP
has been recognised in breast cancer (Fox et al, 1996, 1997a) and
a correlation between TP expression and IMD has been reported
for other solid tumours (Toi et al, 1995a; Matsuura et al, 1999;
Ueda et al, 1999).
IMD and uPA/PAI-1 levels
Background extracellular matrix proteolysis is one of the most
important steps in angiogenesis. The urokinase-type plasminogen
activator system (uPAS) consisting of urokinase plasminogen acti-
vator (uPA), an extracellular proteolytic enzyme produced by
tumour cells, its receptor uPA-R and their corresponding inhibitors
plasminogen activator inhibitors 1 and 2 (PAI-1 and PAI-2) are
thought to play a major role in this process. uPA at the cell surface
initiates a proteinase cascade leading to the breakdown of the
extracellular matrix and thereby promoting cellular migration.
The levels of uPA and its inhibitor PAI-1 are known prognostic
factors in breast cancer. In a series of patients with breast cancer,
uPA and PAI-1 contents were measured by ELISA in tissue
extracts, in peripheral and central tumour tissue (Hildenbrand et
al, 1995). uPA and PAI-1 levels were higher in the peripheral breast
tumour regions, particularly in node-positive patients and there
was a linear correlation between CD31
+ IMD and uPA/PAI-1
levels.
Although these studies have demonstrated a correlation between
particular angiogenic factors and IMD, there have been very few
attempts to examine multiple angiogenic and anti-angiogenic
factors in conjunction with IMD and clearly more work is needed
in this area.
IMD and intra-tumoural microvascular characteristics
It is of particular interest to know the degree to which the radi-
ological assessment of tumour vasculature correlates with IMD. A
number of techniques exist to assess this, including contrast
enhanced magnetic resonance imaging (MRI) (Brasch et al,
2000; Brasch and Turetschek, 2000; Anderson et al, 2001) colour
Doppler ultrasound (Huber et al, 1994; Delorme and Knopp,
1998; Cheng et al, 1999) and positron emission tomography
(Fanelli et al, 1999; Anderson et al, 2001). There is some
evidence to show that radiological imaging can detect differences
in IMD. In one study slow and fast growing subtypes of a R3230
mammary carcinoma were implanted into mice and were subse-
quently analysed for both IMD by FactorVIII-related-antigen
(FVIII-RA) and plasma volume. MR imaging-derived tumour
plasma volume and permeability increased exponentially with
increased capillary density. A more densely structured vasculature
was found in the fast growing tumours and the increased vascu-
lar density correlated with estimates of plasma volume as
assessed by MRI (van Dijke et al, 1996). However, in human
studies these correlations have not been so strong, for instance,
in a recent study of cervical carcinoma there was no clear rela-
tionship between MRI and IMD (Cooper et al, 2000). On the
other hand a study in glioma, where VEGF has been more
strongly implicated in the tumour’s pathogenesis, did identify a
relationship between MRI ﬁndings and IMD (Tynninen et al,
1999).
QUANTIFICATION OF IMD BY
IMMUNOHISTOCHEMISTRY
Despite the fact that the majority of studies have identiﬁed IMD
as an independent prognostic factor in solid tumours, several
studies have questioned the ﬁnding. These discrepancies may
be due to particular tumour biological factors that obscure the
relationship but other issues such as staining methodology have
also been implicated. In part the variation in the relationship
between IMD and prognosis has arisen from a lack of standar-
dised immunohistochemical techniques because of the wide
range of antibodies, antigen retrieval methods, designation of
high and low vessel count groups (cut-off points), patient
groups, therapies and data (vessel quantiﬁcation) interpretation.
The correct identiﬁcation of the vascular hot spot within the
tumour and observer experience are two of the most important
factors. In one study that compared the effects of different meth-
odologies on estimates of tumour vascularity, archival specimens
of breast, lung and oral carcinoma, oral dysplasia and normal
breast tissue were investigated. Pretreatment of sections (enzy-
matic digestion, heating), endothelial markers (vWF-von
Willebrand factor and CD31 antibodies), method of quantiﬁca-
tion (highest microvascular density, average microvascular
density and microvascular volume) and inter-observer variations
were all found to alter the estimated vascularity and interestingly
the treatment of sections before staining was the variable that
most signiﬁcantly altered the calculated vascularity of tumours
(Schor et al, 1998).
In order to overcome some of these problems an international
consensus on the methodology and criteria for evaluation of
IMD has been put forward (Vermeulen et al, 1996). The report
proposes a standard method for IMD assessment and sets quality
control standards aimed at improving reproducibility and inter-
centre comparability with regard to the selection of representative
tissue samples, tissue processing and immunostaining, selection
of areas for microvessel enumeration and the technique of vessel
counting within these areas. A training programme for the inexper-
ienced pathologist is also recommended given the subjective
methodology of vascular hot spot selection and identiﬁcation of
individual microvessels. Few comparative studies have evaluated
the different methods of microvessel quantiﬁcation – manual
counting. Chalkley count and CIAS. Further prospective studies
are needed to deﬁne the method of choice. A standard technique
for the evaluation of IMD would facilitate comparison between
different centres and enable the organisation of conﬁrmatory
multicentre trials on the prognostic and predictive value of IMD
in human solid tumours.
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Intra-tumoural microvessels can be identiﬁed by immunostaining
of endothelial cells. Two categories of human endothelial cell speci-
ﬁc antibodies are currently available: the pan-endothelial cell
markers and antibodies that bind selectively to activated or prolif-
erating endothelium (Table 1). The pan-endothelial markers are
characterised by equal intensity of staining for small and large
vessels and reactivity in both frozen and parafﬁn embedded
samples. The latter feature is of clinical importance in that it facil-
itates their use on archival specimens. Generally, CD31 is utilised
as the pan-endothelial marker of choice for parafﬁn sections. In
a recent review (Fox et al, 2001), when studies on breast cancer
with multivariate analysis that used antibodies to CD31 or CD34
were examined, most revealed a positive association with relapse
free survival (RFS) (13 out of 14) and all for overall survival
(OS) (12 out of 12). With studies using FVIII-RA, only eight out
of 13 were positive for RFS and seven out of 10 for OS.
The problem of antigen speciﬁcity is highlighted by the detec-
tion of CD34 antigen on lymphatic vessels, perivascular stromal
cells as well as other stromal elements while this is compounded
by the absence of FVIII-RA on part of the capillary endothelium
in tumour tissue (Holthofer et al, 1982; Parums et al, 1990;
Traweek et al, 1991; Miettinen et al, 1994). The disadvantages asso-
ciated with staining for CD31 antigen include co-staining of
inﬂammatory cells, but these can be distinguished from endothelial
cells on the basis of morphological differences, and frequent anti-
gen loss due to ﬁxatives that contain acetic acid (Vermeulen et
al, 1996). Microwave antigen retrieval effectively abolishes this
problem but in prospective studies a careful selection of the most
suitable tissue ﬁxation procedure should still be performed.
The ability to distinguish quantitatively between tumour neovas-
cularisation and pre-existing vessels may be important in the
assessment of tumour angiogenesis and could provide more accu-
rate prognostic information. This is now possible using markers for
activated endothelium. These markers are suitable for proliferating
endothelium giving none or poor staining of lymphatics and
normal quiescent blood vessels. They mainly react with fresh or
frozen tissues, their activity in parafﬁn-embedded specimens is
ﬁxation dependent. In a study of 106 patients with breast carcino-
ma, the IMD was assessed using a pan-endothelial marker CD34
and a monoclonal antibody to CD105 that preferentially reacts
with endothelial cells in angiogenic tissues. IMD values for
CD105 expression showed a statistically signiﬁcant correlation with
RFS (P=0.0362) and OS (P=0.0029) in contrast to blood vessel
counts using CD34 that did not correlate with RFS or OS (Kumar
et al, 1999). This discrepancy in ﬁndings between the two markers
could be the result of variability in the reactivity of different
endothelial cell antibodies. While anti-CD105 antibody speciﬁcally
reacts with endothelial cells of blood vessels in tissues undergoing
angiogenesis, anti-CD34 antibody generally binds to endothelial
cells in large blood vessels, although its expression can be dimin-
ished or restricted in some tumour microvessels (Wang et al,
1994). The superiority of the anti-CD105 antibody over anti-
CD34 was recently conﬁrmed in another comparative study in
236 patients with NSCLC (Tanaka et al, 2001). CD105 determined
IMD was a signiﬁcant poor prognostic factor in multivariate analy-
sis (P=0.029) while CD34 determined IMD was not.
The activity of another marker for activated endothelium;
LM609, a monoclonal antibody against integrin avb3 has been
investigated in a cohort of primary breast cancers and in normal
breast tissue as control. LM609 preferentially immunostained
proliferating blood vessels of small calibre within neoplastic tissue
with weak expression of the integrin observed on vessels of normal
tissue. In a series of 197 breast cancers, the expression of integrin
avb3 at the vascular hot spot was the single most signiﬁcant prog-
nostic indicator for RFS in both node-negative and node-positive
patients (Gasparini et al, 1998).
The vascular hot spot
Vascular hot spots are regions of high vascular density within the
tumour and were ﬁrst deﬁned in breast cancer (Weidner et al,
1991). It was hypothesised that vascular hot spots arise from angio-
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Table 1 Endothelial cell-speciﬁc antibodies: immunohistochemical characteristics
Reactivity
Antibody Sensitivity Speciﬁcity Frozen Parafﬁn
Anti-CD31 Stain small and large vessels with Non-speciﬁc in cryostat sections – Positive Positive
equal intensity occasional plasma cell staining in
formalin ﬁxed tissue, no lymphatic
staining
Anti-FVIII-RA Variable staining of large vessels and Monoclonal antibody more speciﬁc, Positive Positive
capillaries, polyclonal antibody more stromal staining with polyclonal
sensitive antibody
Anti-Thrombomodulin Most sensitive for vascular tumours Stains squamous epithelial cells Positive Negative
e.g. angiosarcomas
Anti-CD34 Stains small and large vessels with High, some lymphatic and perivascular Positive Positive
equal intensity in normal and tumour stromal staining
tissue
E9 to CD105 (activated) Small intra-tumoural vessels positive, Weak normal tissue vessel staining Positive Positive
large vessels negative (ﬁxation
dependent)
LM609 to integrin avb3 Preferentially stains small calibre blood Weak expression in blood vessels of Positive Positive
(activated) vessels in neoplastic tissue normal tissues (ﬁxation
dependent)
TEC-11 to endoglin 480% of tumour vessels positive Eak staining of normal endothelial cells, Positive Negative
(activated) weak stromal staining
Adapted from Vermeulen et al (1996). Other endothelial markers in use are UEA-1, type IV collagenase, anti-CD36, PAL-E, BMA120-
BW200, and EN-4. Other activated endothelial markers include EN7/44, 4A11, H4/18 and FB5.
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enter the circulation and give rise to vascularised metastases. These
areas are identiﬁed by an inspection of the tumour at low magni-
ﬁcation. However, this is clearly time consuming when the
diameter of some tumours often exceeds 10 cm. It was suggested
that the number of vascular hot spots analysed should be at least
10 to reduce the chances of missing the most vascular areas
(Martin et al, 1995).
From the practical standpoint, assessment of IMD in selected
areas compared to an overall vascular count is less time consum-
ing. Vascular hot spots are encountered predominantly at the
peripheral tumour margin and can be selected by scanning a
tumour section at low magniﬁcation (10–1006). A low back-
ground staining and highly speciﬁc and intense labelling of
endothelial cells is required. Once the vascular hot spot is deﬁned,
a higher magniﬁcation is selected in order to be able to count indi-
vidual microvessels. Magniﬁcations of the order of 200–4006and
ﬁeld sizes ranging from 0.12 to 1.00 mm
2 have been used (Vermeu-
len et al, 1996). A higher magniﬁcation improves the detail of the
image and allows the identiﬁcation of more single endothelial cell
sprouts. An area larger or smaller than the vascular hot spot will
result in loss of information.
According to an early study (Weidner et al, 1991), any high-
lighted endothelial cells or cell cluster clearly separate from
adjacent microvessels, tumour cells and other connective tissue
elements should be regarded as a distinct countable microvessel.
This deﬁnition has several implications. Neither a lumen nor the
presence of red blood cells is necessary to identify a microvessel.
In addition a cut-off calibre size is not mentioned so that single cell
sprouts as well as larger vessels are thus included in the counts.
Even if distinct clusters give the impression of being part of one
large vessel transfected by the plane of the tissue section more than
once, they are counted as separate microvessels. Strict application
of these objective criteria seems to result in lower inter-observer
variability when analysing pre-deﬁned hot spots.
Quantiﬁcation of stained vessels can be achieved by measuring
highest microvascular density (h-MVD), the average microvessel
density (a-MVD) or the microvascular volume (MVV). The area
of highest microvascular density (the vascular hot spot) is located
by scanning the section at 1006magniﬁcation. In practice, localisa-
tion of the highest density area normally involves counting up to
three different areas. Three different ﬁelds are counted in each of
these areas at 2006magniﬁcation, and the highest value taken as
the h-MVD, expressed as vessels per mm
2. The a-MVD is deter-
mined using the same grid and magniﬁcation (2006) as for h-
MVD and calculating the mean of the vascular counts obtained
in at least 10–15 random ﬁelds for each tissue section. Results
for a-MVD are expressed as mean+standard deviation (vessels
per mm
2) (Schor et al, 1998). The MVV is estimated by point
counting using an eyepiece graticule, which contains 100 points.
Vessels that coincide with the points are counted in 15 ﬁelds
selected randomly across each section (a total of 1500 points)
and yields results expressed as percentage volume.
The Chalkley method resembles that used to determine the
MVV. Tumour sections are scanned at low magniﬁcation to iden-
tify the areas that appear to have the maximum number of discrete
microvessels. At higher magniﬁcations, an eyepiece graticule
containing 25 randomly positioned dots is rotated so that the
maximum numbers of points are on or within the vessels of the
vascular hot spot. Instead of counting the individual microvessels,
the overlying dots are counted. In a series of patients with breast
carcinoma (Fox et al, 1995), a signiﬁcant correlation was found
between MVD assessment by the Weidner method and Chalkley
point counting (r=0.7, P=0.00005). A signiﬁcant reduction in OS
was observed between patients stratiﬁed by Chalkley count in both
univariate (P=0.02) and multivariate analysis (P=0.05). In another
study in patients with node-positive breast carcinoma, Chalkley
score was found to be the most signiﬁcant independent predictor
of outcome by multivariate analysis (Gasparini et al, 1996). In a
series of 330 breast cancers (Rose et al, 2000), Chalkley count
was compared to manual microvessel counting and provided inde-
pendent prognostic value in multivariate analysis (P50.0001 for
RFS, P=0.001 for OS). Manual microvessel counting had no prog-
nostic impact. In another study of 104 malignant mesotheliomas,
IMD as assessed by Chalkley counting was assessed with respect
to other known prognostic factors in malignant mesothelioma.
Chalkley microvessel count was shown to be an independent prog-
nostic factor in multivariate analysis (P=0.006) (Edwards et al,
2001). Since no decisions have to be made on whether adjacent
stained structures are stained microvessels or not, Chalkley point
counting should be a more objective approach.
The ﬁrst problem that arises with the quantiﬁcation techniques
is the selection of a representative tumour block. In colorectal
adenocarcinoma, the IMD in in-situ growth regions is approxi-
mately half of that seen in invasive regions (Vermeulen et al,
1995) suggesting that multiple blocks should be assessed. de Jong
et al (1995) found a higher average coefﬁcient of variation (24%)
if more than one tissue block was analysed compared to a lower
coefﬁcient of variation (15%) when only counts within sections
of one block were examined, indicating that a comprehensive
inspection of available tumour material is needed to identify the
relevant hot spots.
The training and experience of the investigator inﬂuences the
identiﬁcation of the vascular hot spot. Barbareschi et al (1995)
compared the calculated IMD in 91 node negative invasive breast
carcinomas by light microscopy when measured by two patholo-
gists of different experience. Both at univariate and multivariate
analysis, only the counts of the experienced pathologist were signif-
icantly associated with relapse-free survival. Similar results were
noted in another series of node negative breast cancer patients
(Vermeulen et al, 1997). Once the vascular hot spot is identiﬁed,
vessel counts after agreement on the description of a single coun-
table vessel appears to be less dependent on subjective
interpretation than the process of hot spot selection.
Grading of IMD
In addition to the vascular hot spot technique another method is
semiquantitative grading. Several studies have reported a positive
correlation between quantitative and semiquantitative MVD scores.
Weidner et al (1991) subjectively graded angiogenesis in vascular
hot spots and counted individual microvessels in the same ﬁelds
(Weidner et al, 1992). MVD values obtained by both methods were
a statistically signiﬁcant predictor of RFS and OS. The obvious
advantage of IMD grading is its time efﬁciency. However, transla-
tion of a continuum of MVD values into a categorical type of data
will however be associated with some loss of information. Given
the highly subjective nature of IMD grading, comparable results
will only be obtained by different observers after a period of train-
ing with standardised methods.
Computerised Image Analysis systems (CIAS)
This is an automated counting technique that improves reproduci-
bility and reduces inter-observer variability and has been proposed
as a more objective method of assessing IMD (Wakui et al, 1992;
Visscher et al, 1993). In a series of 91 node-negative invasive ductal
carcinomas of the breast, both the number of CD31 positive
microvessels measured by an experienced observer and the micro-
vessel area (MVA) determined by CIAS were independently
associated with RFS (Barbareschi et al, 1995). Fox et al (1995) also
reported comparable results in another series of patients with
breast carcinoma.
The main advantage of CIAS is the additional morphometric
parameters that can be detected i.e. the number of vessels with a
certain dimension range, the vessel luminal area, vessel luminal
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scopic ﬁeld. IMD can be measured more objectively without the
intervention of an investigator. The apparent disadvantage of CIAS
is the time consuming nature of the method and its higher cost.
These systems are not fully automated yet and require a high
degree of operator interaction. The vascular hot spot is still identi-
ﬁed manually before automated counting as the heterogeneity of
microvessel morphology and immunostaining intensity particularly
hampers a fully automated analysis of tumour IMD.
IMD AND METASTASIS
As tumour metastasis is the major cause of mortality in cancer
patients, a classiﬁcation of the metastatic potential of a tumour
could be of great clinical signiﬁcance. A quantitative relationship
between IMD, the number of intravascular tumour cells and the
occurrence of pulmonary metastasis was shown in an animal
tumour model more than 20 years ago (Liotta et al, 1974) but clin-
ical conﬁrmation has only been revealed in the last few years
(McCulloch et al, 1995). Before surgery for patients with primary
breast cancer, a central venous catheter was ﬁxed in the ipsilateral
subclavian vein. Blood samples were taken before, during and 1 day
after surgery and tumour cells were identiﬁed on the basis of cyto-
keratin positivity. Microvessels were highlighted with anti-CD34
antibody in tissue sections of the invasive tumour component
and the IMD was measured in the vascular hot spots. The majority
of patients with a high vascular density had cells detected during
operation in contrast to a minority of patients with a low IMD,
suggesting that the frequency of tumour cell shedding was related
to IMD (r=0.56, P=0.024).
Evidence that the intensity of angiogenesis in a human tumour
could predict the probability of metastasis was initially reported in
cutaneous melanoma (Srivastava et al, 1986, 1988). There was a
clear distinction between a stage without neovascularisation, which
correlated with a low rate of metastasis, and a stage in which
increasing neovascularisation correlated with an increased rate of
local and distant metastasis (P=0.025). Weidner et al (1991), in
one of the earliest studies, reported a signiﬁcant correlation
between the degrees of IMD at the vascular hot spot with the prob-
ability of metastasis in a series of 49 patients with invasive breast
cancer. Using light microscopy, blood vessels were highlighted by
staining their endothelial cells immunocytochemically for factor
VIII. The microvessels were counted (per 2006field), and their
density graded (1–4+) in the most active areas of neovascularisa-
tion. Both microvessel counts and density grades were found to
correlate with metastatic disease. For each 10-microvessel increase
in the vessel count per 2006field, there was a 1.17-fold increase
in the risk of distant metastasis (P=0.029). In another series of
patients with node-negative breast cancer, assessment of IMD by
immunohistochemistry with anti-CD31 antibody, IMD correlated
signiﬁcantly with recurrence in viscera, bone and soft tissue depos-
its (Gasparini et al, 1994). Several studies have now shown that
highly vascularised tumours have a signiﬁcantly higher likelihood
to present with loco-regional lymph node metastasis than those
that are poorly vascularised. Likewise a similar correlation between
IMD in the primary tumour and the development of distant metas-
tasis was found (Table 2).
The expression levels of genes that regulate metastasis and
angiogenesis can predict metastatic potential in individual patients.
This was demonstrated in a study of 46 renal cancers (Slaton et al,
2001). The expression levels of basic ﬁbroblast growth factor,
vascular endothelial growth factor, interleukin-8 (IL-8), matrix
metalloproteinases (MMP) 2 and 9 and E-cadherin were examined
at the periphery of the tumour by a colorimetric in situ mRNA.
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Table 2 Clinicopathological studies of IMD and metastasis
Endothelial Tumour Number of
Association with metastasis
Author marker type patients Nodal P Distant P
Weidner et al (1991) FVIII-RA Breast 49 0.003 0.003
Hall et al (1992) FVIII-RA Breast 87 NS NS
Ogawa et al (1995) FVIII-RA Breast 155 No correlation ND
Fox et al (1997b) CD-31 Breast 214 NS 0.01
Arapandoni-Dadioti et al (1999) CD31 Breast 35 0.006 ND
Hansen et al (2000) CD-34 Breast 836 NS 0.01
Elpek et al (2001) CD34 Oesophagus 53 50.05 ND
Maeda et al (1995) FVIII-RA Gastric 124 50.01 NS
Tanigawa et al (1997) CD-34 Gastric 181 0.11 0.0001
Xiangming et al (1998) FVIII-RA Gastric 97 0.0016 ND
Oh-e et al (2001) CD34 Colon 254 0.0026 ND
Vermeulen et al (1999) CD34 Colon 145 NS 0.001
Gasparini et al (1995b) CD-31 Head and neck SCC 70 0.004 0.004
Lane et al (1997) UEA-1 Uveal melanoma 63 ND NS
Macchiarini et al (1992) FVIII-RA NSCLC 87 50.0001 50.0001
Fontanini et al (1995) FVIII-RA NSCLC 253 50.000001 0.01
(dichotomous
variable)
P=0.003
(continuous
variable)
Weidner et al (1993) FVIII-RA Prostate 74 ND 50.0001
(bone marrow
mets only)
Halvorsen et al (2000) FVIII-RA Prostate 104 0.0084 ND
(clinical recurrence)
Olivarez et al (1994) FVIII-RA Testicular germ cell 65 0.011 ND
tumour
Fukuda et al (1999) FVIII-RA Testicular germ cell 80 ND P50.001
tumours
ND, not done; NS, not signiﬁcant.
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signiﬁcantly higher in primary renal tumours from patients with
synchronous or metachronous metastases than those who were
disease free at a median of 48 months of follow up. Multivariate
analysis of RFS showed that the ratio of MMP-9 to E-Cadherin
(P=0.012) and the expression level of bFGF expression (P=0.045)
were independent predictors for the development of metastases.
The expectation that determination of an angiogenic index by
IMD can identify all patients with occult metastatic disease or
those with probable distant metastasis is probably unrealistic.
Human tumours are heterogeneous and consist of subpopulations
of cells with different biological properties. Secondly, the process of
development of metastasis consists of a series of interlinked inde-
pendent steps. To produce clinically relevant metastasis, tumour
cells must complete all the steps in this process. Tumour cells that
can induce intense angiogenesis but cannot survive in the circula-
tion or proliferate in distant organs will not produce metastasis
(Ellis and Fidler, 1996). Like the other steps in the metastatic
cascade, angiogenesis is necessary but not sufﬁcient for the patho-
genesis of metastasis.
IMD AS A PREDICTIVE MARKER OF RESPONSE TO
ANTI-CANCER THERAPY
Although IMD has been shown to correlate with metastasis and
survival one might anticipate that the increased vascularity may
improve tumour oxygenation and drug delivery thereby improving
the response to therapy. However, the converse has generally been
reported (Table 3). In a study of patients with squamous cell carci-
noma of the head and neck treated with concurrent
chemoradiation, the degree of IMD was signiﬁcantly predictive of
poor response to platinum-based chemotherapy in terms of
complete response (P=0.045) (Gasparini et al, 1995b). Similar ﬁnd-
ings have been observed in patients with epithelial ovarian cancers
treated with platinum-based combination chemotherapy (Hollings-
worth et al, 1995).
If patients present with highly angiogenic primary tumours and
these are the patients most likely to develop distant recurrences,
then it might follow that this group of patients are most likely
to beneﬁt from adjuvant therapy. However in contrast to this
hypothesis, the above studies demonstrate that angiogenic tumours
have a more aggressive phenotype and do not beneﬁt as antici-
pated. Perhaps tumours of low angiogenic index are more likely
to beneﬁt from adjuvant therapy even though they are also the
subgroup of patients least likely to develop a recurrence. Perhaps
patients with highly angiogenic tumours should therefore be
selected for trials that include the use of anti-angiogenic strategies.
The general observation from the above data is thus that the great-
er the degree of vascularisation in a solid tumour, the lower the
likelihood of responsiveness to conventional anti-cancer therapy
although this conclusion needs further evaluation in well-designed
prospective studies.
IMD AND PROGNOSIS
If IMD is associated with metastasis then it is logical to predict that
IMD will also be associated with survival and this has been evalu-
ated in most solid tumours including breast, ovary, bladder, head
and neck and prostate cancers amongst others (Tables 4 and 5).
Two pivotal independent studies by Horak et al (1992) and Weid-
ner et al (1992) found that IMD is a signiﬁcant and independent
prognostic factor in human invasive breast cancer. In a prospective
blinded study of 165 patients with breast cancer, Weidner and
Folkman showed that there was a highly signiﬁcant association
between IMD and RFS and OS in both node-negative and node-
positive subsets (P=0.01). All patients with breast carcinomas
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Table 3 IMD and prediction of efﬁcacy of anti-cancer therapy
Author Endothelial Tumour Number of Prediction of
(year) marker type patients Treatment efﬁcacy (P value)
Weidner et al (1992) FVIII-RA Breast 82 Heterogeneous Yes (P50.001 for RFS
adjuvant treatments and OS)
Gasparini et al (1993) FVIII-RA Breast 42 Neoadjuvant or palliative No
chemotherapy
Gasparini et al (1995a) CD-31 Breast 191 Adjuvant chemotherapy or Yes (P50.01 for RFS
endocrine therapy and OS)
Toi et al (1995b) FVIII-RA Breast 198 Heterogeneous adjuvant Yes (P50.05 for RFS)
treatments
Macaulay et al (1995) CD-31 Breast 88 Adjuvant tamoxifen Yes for RFS in ER
positive cases,
P=0.022)
Gasparini et al (1996) CD-31 Breast 178 Adjuvant tamoxifen Yes (P50.01 for RFS
and OS)
Vacca et al (1994) FVIII-RA Multiple myeloma 46 Various schedules Yes (active vs no active disease
response P=0.045)
Gasparini et al (1995b) CD-31 Head and neck SCC 73 Concurrent Yes (CR vs no response
chemoradiotherapy P=0.045)
Aebersold et al (2000) CD-31 Oropharynx 139 XRT Yes (P=0.0001 for RFS)
Kamijo et al (2000) CD-31 Larynx 31 XRT Yes (for radiosensitivity
P=0.008
Hollingsworth et al (1995) CD-34 Ovary 43 Platinum-based Yes (P=0.064 for OS,
chemotherapy P=0.0036 for RFS)
Van Diest et al (1995) Lectin-Ulex Ovary 49 Platinum-based No (only a trend for
europaeus-1 chemotherapy worse OS)
Gasparini et al (1998) CD-31 Ovary 60 Platinum-based Yes (P50.01 for poor
chemotherapy response)
Cooper et al (1998) FVIII-RA Cervix 111 XRT Yes for OS (P=0.041)
Cooper et al (1999) FVIII-RA Cervix 74 XRT No correlation between
IMD and intrinsic
radiosensitivity
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(10), 1566–1577containing more than 100 microvessels per 2006field experienced
tumour recurrence within 33 months of diagnosis, compared with
less than 5% of patients with breast cancer having 33 or fewer
microvessels per 2006field. Moreover IMD was the only statisti-
cally signiﬁcant predictor of OS in node-negative patients
(P50.001). In the study by Horak et al (1992) microvessels were
counted in 103 patients with primary breast cancer using the
JC70 antibody to CD31. Tumours showed signiﬁcantly higher
vascularisation than normal breast tissue and the number of blood
vessels/mm
2 was signiﬁcantly associated with node metastasis
(P50.00001). Vascularity was correlated with the size of the
primary tumour and with poor differentiation. Within each
subgroup of size or differentiation, tumours without nodal involve-
ment had much lower IMD. Even with the short follow up in this
study, high vascular counts correlated with early deaths.
Over a hundred retrospective studies have been published on the
prognostic signiﬁcance of IMD in solid tumours. In breast cancer
alone more than 40 retrospective studies have been published with
more than 7000 patients evaluated. Since these patients have differ-
ent pathological and clinical characteristics, a proper metaanalysis
is not possible. Nevertheless more than 75% of studies reported
positive results on the association of IMD with clinical outcome
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Table 4 IMD and prognosis in breast cancer
Number of Endothelial Nodal
Univariate analysis
(P-value)
Multivariate analysis
(P-value)
Author patients marker status RFS OS RFS OS
Weidner and Gasparini (1994) 165 FVIII-RA N7/N+ 50.001 50.001 50.0001 50.001
Ogawa et al (1995) 155 FVIIII-RA N7/N+ 50.001 50.025 50.002 50.0001
Toi et al (1995b) 328 FVIII-RA N7/N+ 50.001 ND 50.0001 ND
Axelsson et al (1995) 220 FVIII-RA N7/N+ NS NS NS NS
Kato et al (1999) 109 FVIII-RA N7/N+ ND 0.02 ND 0.04
Medri et al (2000) 378 FVIII-RA N7 0.018 ND NS ND
Guidi et al (2000) 110 FVIII-RA N+ 0.006 0.007 0.02 0.007
Fridman et al (2000) 216 FVIII-RA N7/N+ NS NS ND ND
Vincent-Salomon et al (2001) 685 FVIII-RA N7/N+ NS NS NS NS
Gasparini et al (1994) 254 Anti-CD31 N7 0.0001 0.012 0.0004 0.047
Fox et al (1994) 109 Anti-CD31 N7 0.01 0.028 0.04 0.01
Fox et al (1995) 211 Anti-CD31 N7/N+ ND 0.02 ND 0.05
Gasparini et al (1995a) 191 Anti-CD31 N+ 50.01 50.01 50.01 50.01
Bevilacqua et al (1995) 211 Anti-CD31 N75 0.0001 50.018 50.0001 50.044
Gasparini et al (1996) 178 Anti-CD31 N+ 50.01 50.01 50.01 50.01
Jacquemier et al (1998) 201 Anti-CD31 N7/N+ 0.0002 0.0037 0.0002 0.05
Viens et al (1999) 155 Anti-CD31 N+ 0.004 0.006 0.003 0.007
Heimann et al (1996) 167 Anti-CD34 N7 0.018 ND 0.04 ND
Hansen et al (2000) 836 Anti-CD34 ND 50.0001 50.0001 50.001 50.001
Gasparini et al (1998) 197 LM609 N7/N+ 50.0001 0.0001 50.0001 ND
Kumar et al (1999) 106 Anti-CD105 N7/N+ 50.001 0.003 50.01 50.01
Table 5 Studies on IMD and prognosis in solid tumours
Endothelial Number of
Univariate analysis Multivariate analysis
Tumour type Author marker patients RFS OS RFS OS
Male urogenital
Renal Slaton et al (2001) CD34 46 NS ND NS ND
Bladder Bochner et al (1995) FVIII-RA 164 P50.0001 P50.00077 P50.05 P50.05
Prostate Borre et al (1998) FVIII-RA 221 P=0.0001 ND P=0.0004 ND
Female urogenital
Ovary Obermair et al (1999) CD34 63 ND NS ND P=0.038
Fallopian tube Bancher-Todesca et al (1999) CD34 43 0.046 ND ND ND
Endometrial Giatromanolaki et al (2001) CD31 121 ND P=0.0001 ND P=0.01
Cervix Cooper et al (1999) FVIII-RA 89 ND P=0.035 ND P=0.007
GI tract
Oesophagus Elpek et al (2001) CD34 53 ND P=0.0001 ND P50.01
Gastric Maeda et al (1996) FVIII-RA 124 ND P50.05 ND P=0.048
Colorectal Saclarides et al (1994) FVIII-RA 48 P=0.013 ND ND
Pancreas Fujioka et al (2001) CD31 104 ND ND P=0.013 ND
Thoracic
Lung Fontanini et al (1997) CD34 407 ND P50.00001 ND P50.00001
Mesothelioma Edwards et al (2001) CD34 104 ND P=0.01 ND P=0.006
Others
Brain Li et al (1994) FVIII-RA/CD34 26 P=0.005 P=0.02 ND ND
Melanoma Straume et al (1999) FVIII-RA 102 ND P=0.04 ND P=0.1
Head and neck Gasparini et al (1995b) CD31 73 NS NS NS NS
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British Journal of Cancer (2002) 86(10), 1566–1577 ã 2002 Cancer Research UKand more than 85% of the 27 studies, which included multivariate
analysis, found that IMD was an independent prognostic variable
(Gasparini and Harris, 1995; Ellis et al, 1998; Gasparini, 2001)
and these ﬁndings have been observed in both the adjuvant and
metastatic disease settings (Gasparini et al, 1995a, 1996; Macaulay
et al, 1995; Toi et al, 1995b). The bulk of accumulating data indi-
cates that IMD in the area of most intense neovascularisation in
invasive breast cancer is an independent, signiﬁcant and accurate
prognostic marker in predicting poorer survival. Such an indicator
might be potentially useful in tailoring adjuvant therapy for high-
risk breast cancer patients although there is no data at present link-
ing aggressive treatment to better outcome in such patients. Clearly
prospective evaluation of this area is required.
The prognostic value of IMD has been studied in other solid
tumours apart from breast cancer. These include cancers of the
lung, genito-urinary tract, GI tract, head and neck, gynaecological
malignancies and malignant melanomas. In the largest single series,
IMD was assessed prospectively in 407 patients with stages I–III
non-small cell lung cancer (NSCLC). Anti-CD34 antibody was used
to measure angiogenesis in tumour samples. In multivariate analy-
sis IMD, tumour microvessel count (P50.00001), tumour size and
regional lymph node status retained independent prognostic value
with respect to overall survival. Among these variables, tumour
microvessel count considered as a continuous variable was the
most important (Fontanini et al, 1997).
Poor associations between IMD and survival
There are several reports that do not demonstrate a relationship
between IMD and survival (Hall et al, 1992; van Hoef et al, 1993;
Axelsson et al, 1995; Costello et al, 1995; Goulding et al, 1995;
Morphopoulos et al, 1996). While these studies may reﬂect a genu-
ine biological ﬁnding there are a number of technical issues that
may confound studies. For instance a discrepancy may be related
to potential methodological pitfalls in case selection, small study
populations, heterogeneous therapy, inadequate follow-up and
statistical analysis. Issues related to the application of immunohisto-
chemical techniques including choice of endothelial marker, the
vascular variable quantiﬁed and the area of tumour section assessed
and inter-observer variability could also contribute. On the other
hand, the tendency for positive results to be published may have
led to an exaggerated assessment of the importance of IMD.
It is possible that some tumours are less angiogenesis-dependent
than others. For example, in intestinal-type gastric cancer, vessel
counts correlate with stage of disease and metastasis formation
(Takahashi et al, 1996). In contrast vessel counts in diffuse-type
gastric cancer do not correlate with metastasis and in general vessel
counts in diffuse-type gastric cancer are lower those seen in intest-
inal-type gastric cancer.
Tumours may also be able to grow without neovascularisation if
a suitable vascular bed is available. The pattern of vascularisation
was studied in 500 cases of non-small cell lung cancer. Of these
80 (16%) were characterised by an absence of stroma and lack of
new vessel formation (Pezzella et al, 1997). In such cancers, the
degree of neovascularisation as assessed by IMD may not be of
prognostic value. On the other hand, in colon cancer, the presence
of ulceration and adjacent inﬂammation may itself contribute to
increased local vascularity independent of the tumour and may
confound results (Abdalla et al, 1999). Discordant results from
studies may also reﬂect the fact that angiogenesis is but one step
in the multistep process of metastasis. If a primary tumour has a
high angiogenic index, but does not express other factors necessary
for metastasis formation (i.e. adhesion/cohesion molecules, motility
factors, growth factor receptors, etc.), then despite the high degree
of angiogenesis, metastasis will not occur.
A further mechanism by which the discrepancy between IMD
and survival may occur is vasculogenic mimicry, which has been
described in melanoma. In aggressive primary and metastatic mela-
nomas, the tumour cells generate microcirculatory channels
composed of extracellular matrix that are lined by tumour cells
(Maniotis et al, 1999; Folberg et al, 2000). The channels generated
through this process by tumour cells may not stain with endothe-
lial cell markers, as endothelial cells are not present.
Despite the fact that the overall trend in most studies is that the
assessment of IMD retains a prognostic value in the majority of
solid tumours, no deﬁnitive conclusions can be drawn at present
on the real clinical usefulness of this approach. Before adopting
IMD as a prognostic marker in routine clinical application, appro-
priate prospective trials are needed to validate the results observed
in retrospective studies. Furthermore the method of assessment of
IMD is inconsistent and needs to be standardised and made more
objective.
CONCLUSION
There is sufﬁcient evidence to justify the determination of IMD as
a measure of the angiogenic activity of human solid tumours. This
method may be improved by employing more selective and speciﬁc
markers for activated/proliferating endothelium, improving stain-
ing techniques, using more objective and reproducible methods
for microvessel counting and standardisation of the criteria for
evaluation of IMD and of the identiﬁcation of the neovascular
hot spot within each tumour.
As alternative methods like serum and tissue sampling of angio-
genic peptides, measurement of endothelial cell proliferation, cell
adhesion molecules and proteolytic enzymes as well as dynamic
contrast enhanced MRI become available, these may enhance the
accuracy of the measurement of angiogenic activity in solid
tumours.
A strong correlation has been conﬁrmed between the IMD of a
primary tumour and its potential to develop locoregional or distant
metastasis. Assessment of tumour vascularity is now an established
prognostic indicator in early stage breast cancer, NSCLC and
prostatic carcinoma (Gasparini and Harris, 1999). In these tumour
types, the majority of retrospective studies found a signiﬁcant
correlation between vascularisation of the primary tumour and
clinical outcome of patients. In other tumour types the role of
IMD remains investigational and requires well-designed prospective
studies. Preliminary studies suggest that the determination of
angiogenesis may serve as a marker to predict response to some
forms of conventional anti-cancer therapy. An inverse relationship
between the degree of vascularisation and responsiveness to anti-
cancer therapy has been shown in the adjuvant setting as well as
for advanced tumours.
Certain issues remain unresolved. Besides the technical standar-
disation issues, it is unclear whether antibodies directed against
activated endothelium will predict metastasis and survival better
than other pan-endothelial methods. This issue needs to be
addressed in a large study before we can establish prospective trials
that are ultimately needed to validate IMD as a guide to therapy.
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